NEXI

Neximmune Inc

NEXI, USA

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a vivo directly injectable modality platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It also provides NEXI-004 which is in preclinical stage for EBV related diseases. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

https://www.neximmune.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
NEXI
stock
NEXI

A Look At Nexi (BIT:NEXI) Valuation As Efficiency Efforts And Consolidation Rumors Draw Investor Focus simplywall.st

Read more →
NEXI
stock
NEXI

Is Nexi (BIT:NEXI) Tightening Costs To Defend Its Moat Or Mask Strategic Uncertainty? simplywall.st

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2024-06-30)

Rating:

HOLD

Target Price:

$2

Analyst Picks

Strong Buy

0

Buy

0

Hold

1

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2024-06-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.00

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-252.76 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-39.70 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very Low

5.37

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 5.08% of the total shares of Neximmune Inc

1.

Sabby Management LLC

(3.5782%)

since

2024/06/30

2.

Raymond James & Associates

(0.7747%)

since

2024/09/30

3.

JPMorgan Chase & Co

(0.2868%)

since

2024/06/30

4.

Comerica Bank

(0.2335%)

since

2024/06/30

5.

Tower Research Capital LLC

(0.1521%)

since

2024/06/30

6.

UBS Group AG

(0.0457%)

since

2024/06/30

7.

SSgA U.S. Total Market Index Strategy

(0.0033%)

since

2024/06/30

8.

BNP Paribas Arbitrage, SA

(0.0029%)

since

2024/06/30

9.

Bank of America Corp

(0.0005%)

since

2024/06/30

10.

Royal Bank of Canada

(0%)

since

2024/06/30

11.

Wells Fargo & Co

(0%)

since

2024/06/30

12.

EPIQ Capital Group, LLC

(0%)

since

2024/09/30

13.

Slate Path Capital LP

(0%)

since

2024/09/30

14.

Vanguard Group Inc

(0%)

since

2024/09/30

15.

PNC Financial Services Group Inc

(0%)

since

2024/09/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2024-06-30

EPS Actual

-1.6856

EPS Estimate

—

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2024-06-30)

Deep Value
Potential Value Candidate(5)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
No Clear Moat(2.8)
GARP
Not Attractive for GARP(1)
Growth
Weak Growth Prospect(1)
Momentum
No Momentum(2)
Net Net
Possible Net-Net(4)
Quality
Low Quality Business(1)
Value
Fair Value(5)

Income Statement

(Last Updated 2024-06-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2024-06-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2024-06-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.